Alnylam Pharmaceuticals Inc
ALNY
NASDAQ
Biotechnology
$228.65
USD
+1.53 (+0.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $30.39B
Volume 1.5M
Revenue
$4.80B
TTM
+95.1%
YoY
Gross Margin
80%
TTM
-4.9%
YoY
Net Income
$807.99M
TTM
+382.7%
YoY
Operating Cash Flow
$885.89M
TTM
+2236.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 773.7 | 1,249.0 | 1,097.0 | 1,167.2 | 1,290.9 |
YoY Growth | +17.3% | +149.3% | +84.9% | +96.4% | +66.9% |
Cost of Revenue | 142.0 | 197.2 | 267.7 | 207.5 | 298.3 |
Gross Profit | 631.7 | 1,051.8 | 829.3 | 959.7 | 992.7 |
Selling, General & Administrative | 323.3 | 322.1 | 325.4 | 322.6 | 347.9 |
Other Operating Expenses | 0.9 | 2.9 | 0.0 | 3.6 | 0.2 |
Total Operating Expenses | 647.9 | 683.8 | 697.6 | 691.0 | 761.2 |
Operating Income | -16.2 | 368.0 | 131.7 | 268.6 | 231.4 |
EBITDA | -2.3 | 381.8 | 145.2 | 282.2 | 245.3 |
Other Income / Expense | 8.9 | -113.3 | 132.1 | -4.3 | 0.3 |
Total Other Income / Expense | -25.1 | -129.0 | 29.4 | -47.0 | -53.6 |
Income Before Income Taxes | -41.3 | 239.0 | 161.1 | 221.7 | 177.8 |
Income Taxes | 30.9 | -12.1 | -25.3 | 15.7 | 13.3 |
Net Income | -72.2 | 251.1 | 186.4 | 206.0 | 164.5 |
Consolidated Net Income / Loss | -72.2 | 251.1 | 186.4 | 206.0 | 164.5 |
Net Income Attributable to Common Shareholders | -72.2 | 251.1 | 186.4 | 206.0 | 164.5 |
Basic EPS | -$0.55 | $1.91 | $1.41 | $1.55 | $1.23 |
Diluted EPS | -$0.55 | $1.84 | $1.32 | $1.51 | $1.21 |
Basic Shares Outstanding | 130.6M | 131.4M | 132.3M | 132.9M | 133.6M |
Diluted Shares Outstanding | 130.6M | 137.3M | 141.1M | 138.2M | 138.3M |